Analystreport

C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com